Factive
Home >> Factive >> Drug Details
Gemifloxacin mesylate (trade name Factive, Oscient Pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Oscient Pharmaceuticals has licensed the active ingredient from LG Life Sciences of Korea.
Indications
Gemifloxacin is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Community-acquired pneumonia (of mild to moderate severity) caused by S. pneumoniae (including multi-drug resistant strains, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae.
Microbiology
Gemifloxacin has been shown to be active against most strains of the following microorganisms:
- Aerobic gram-positive microorganisms - Streptococcus pneumoniae[1]
including multi-drug resistant Streptococcus pneumoniae (MDRSP). MDRSP includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
- Staphylococcus aureus (methicillin-susceptible strains only) and Streptococcus pyogenes
- Aerobic gram-negative microorganisms - Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae (many strains are moderately susceptible), Moraxella catarrhalis, Acinetobacter lwoffii, Klebsiella oxytoca, Legionella pneumophila, Proteus vulgaris.
- Other microorganisms - Chlamydia pneumoniae, Mycoplasma pneumoniae
Adverse effects
Fluoroquinolones are generally well tolerated with most side effects being mild and serious adverse effects being rarely.[2][3] Some of the serious adverse effects which occur more commonly with fluoroquinolones than with other antibiotic drug classes include CNS and tendon toxicity.[4][5] The currently marketed quinolones have safety profiles similar to that of other antimicrobial classes.[6]
The serious events may occur with therapeutic or with acute overdose. At therapeutic doses they include: central nervous system toxicity, cardiovascular toxicity, tendon / articular toxicity, and rarely hepatic toxicity.[7] Events that may occur in acute overdose are rare and include: renal failure and seizure.[7] Children and the elderly are at greater risk.[5][2] Adverse reactions may manifest during, as well as after fluoroquinolone therapy.[8]
Some groups refer to these adverse events as "fluoroquinolone toxicity". These groups of people claim to have suffered serious long term harm to their health from using fluoroquinolones. This has led to a class action lawsuit by people harmed by the use of fluoroquinolones as well as action by the consumer advocate group Public Citizen.[9][10] Partly as a result of the efforts of Public Citizen the FDA ordered a black box warnings on all fluoroquinolones advising consumers of the possible toxic effects of fluoroquinolones on tendons.[11]
See also
References
- ^ Calvo A, Gimenez MJ (2002). "Ex Vivo Serum Activity (Killing Rates) After Gemifloxacin 320 mg Versus Trovafloxacin 200 mg Single Doses Against Ciprofloxacin-Susceptible and -Resistant Streptococcus pneumoniae". Int. J. Antimicrob. Agents 20 (2): 144-6. PMID 12297365.
- ^ a b Owens RC, Ambrose PG (July 2005). "Antimicrobial safety: focus on fluoroquinolones". Clin. Infect. Dis. 41 Suppl 2: S14457. doi:10.1086/428055. PMID 15942881.
- ^ Ball P, Mandell L, Niki Y, Tillotson G (November 1999). "Comparative tolerability of the newer fluoroquinolone antibacterials". Drug Saf 21 (5): 40721. PMID 10554054.
- ^ Owens RC, Ambrose PG (July 2005). "Antimicrobial safety: focus on fluoroquinolones". Clin. Infect. Dis. 41 Suppl 2: S14457. doi:10.1086/428055. PMID 15942881. http://www.journals.uchicago.edu/cgi-bin/resolve?CID34940.
- ^ a b Iannini PB (June 2007). "The safety profile of moxifloxacin and other fluoroquinolones in special patient populations". Curr Med Res Opin 23 (6): 140313. doi:10.1185/030079907X188099. PMID 17559736.
- ^ Owens RC, Ambrose PG (July 2005). "Antimicrobial safety: focus on fluoroquinolones". Clin. Infect. Dis. 41 Suppl 2: S14457. doi:10.1086/428055. PMID 15942881. http://www.journals.uchicago.edu/cgi-bin/resolve?CID34940.
- ^ a b Nelson, Lewis H.; Flomenbaum, Neal; Goldfrank, Lewis R.; Hoffman, Robert Louis; Howland, Mary Deems; Neal A. Lewin (2006). Goldfrank's toxicologic emergencies. New York: McGraw-Hill, Medical Pub. Division. ISBN 0-07-143763-0. OCLC url=http://books.google.com/books?id=cvJuLqBxGUcC&pg=PA849&dq=goldfranks+Fluoroquinolone+toxicity.
- ^ Saint F, Gueguen G, Biserte J, Fontaine C, Mazeman E (September 2000). "[Rupture of the patellar ligament one month after treatment with fluoroquinolone]" (in French). Rev Chir Orthop Reparatrice Appar Mot 86 (5): 4957. PMID 10970974. http://www.masson.fr/masson/MDOI-RCO-09-2000-86-5-0035-1040-101019-ART7.
- ^ http://www.consumeraffairs.com/news04/2006/08/pubcit_cipro.html
- ^ http://www.mnd.uscourts.gov/MDL-Levaquin/index.shtml
- ^ "FDA orders 'black box' label on some antibiotics". http://www.cnn.com/2008/HEALTH/07/08/antibiotics.risk/index.html. Retrieved 2008-07-08.
Return to Top  Start a New Discussion About this Drug
This article is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License)
http://en.wikipedia.org/wiki/Factive
This information has been independently compiled and is for educational purposes only. It is not intended to be a substitute for face to face medical advice from a qualified healthcare professional. Please remember that the content within this community is totally compiled by users of this site. Our website displays many pages which do not contain any medical information regarding the drug name stated. These pages are only provided for the purpose of opening community discussions about that drug by our users. For more details please see the Disclaimer. This data is Copyright © 2005-2009 PrescriptionDrug-Info.com and is protected under U.S. and International Copyright laws. All Rights Reserved.
drug_details.asp Last Updated November 9 2009
|
 Home Page
Post Your Story or Question
 Follow Us On Twitter
 Registered Community Experts
Topics Submitted 
Prescription Drug Forums
Top 200 Prescription Drugs
Drugs by Category
Recent FDA Approvals
November 2009 Health News
Advertising & Contact Details
About the Community
Medical Disclaimer
Terms of Use
Privacy Policy
Make Us Your Home Page
Bookmark this Page 
Recent Topics
Watson 540 Mg
Ip 101
Xodol
Peach I Over 25
Ip 144
Trochlorterazine
V 36 01
Autism
500 Vk Vk 500
M362
Qvar
Remicade
Ku 262
A 76 7m
Neurostin
Ip 113
Durahist
Nizagara
I9
Saboxin
Small Round Scored Blank White Pill
Yellow Pill 9652
Norco
Amlodipin Tab 5mg
White Oval Pill X 10
M366
Ciprofloxacin Ta 500mg Cip
25 41 V
00 20
Lupin 20mg
|
Committed to Your Privacy 
